Pharmaceuticals Acquisitions in Connecticut

Merck KGaA, Darmstadt, Germany completed the acquisition of SpringWorks Therapeutics, Inc. for an enterprise value of $3.4 billion (US$47 per share in cash), following regulatory clearances and customary closing conditions. The deal adds SpringWorks' rare tumor portfolio — including OGSIVEO (nirogacestat) and GOMEKLI (mirdametinib) — to Merck's Healthcare business and is expected to be accretive to earnings by 2027 while strengthening Merck's rare tumor capabilities.

Pfizer Inc. completed the acquisition of Biohaven Pharmaceutical Holding Company Ltd. for approximately $11.6 billion (at $148.50 per share), bringing the migraine therapy NURTEC ODT (rimegepant), the zavegepant NDA program, and a CGRP-focused pipeline into Pfizer's Internal Medicine portfolio. Prior to closing, Biohaven spun off its non-CGRP assets into a separate publicly traded company, Biohaven Ltd., which Pfizer received a small pro rata stake in.

The Vistria Group and Excellere Partners purchased all outstanding equity interests of SCA Pharmaceuticals from Enhanced Healthcare Partners. SCA Pharma, an FDA-registered 503B outsourcing facility with sites in Windsor, Connecticut and Little Rock, Arkansas, will continue to be led by CEO Milton Boyer while the new owners plan to accelerate facility expansion, automation and growth.